Context
Nowadays, particle-size reduction of API’s (Active Pharmaceutical Ingredients) is highly desirable because it helps improve bioavailability, considering the fact that poorly soluble drugs constitute a large proportion of the APIs currently on the market reducing particle size could enable new administration routes or change existing formulations with lower API doses to reduce toxicity.
This particle-size reduction is traditionally achieved by jet-milling, a technique that is over a century old, and at best yields particles 2-3 µm in diameter.
New technologies have been sought to further reduce particle size, and this search has given rise to the field of API Nanocrystal technology.
We want to introduce a disruptive technology regarding the particle size reduction of pure crystalline API’s that offers the following benefits: production of particles with crystalline structures (amorphous phase possible with other technology’s), reduction of particles from millimeters to nanometers, applicable to all types of powders…
Through this questionnaire, we would like to better understand the market needs for this process and find potential partners for further innovative and disruptive approaches, subcontractors, or clients.
